{"schema_version":"secwatch.filing_event.v1","accession":"0001555280-25-000201","form_type":"8-K","ticker":"ZTS","cik":"0001555280","company_name":"Zoetis Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.747485+00:00","generated_at":"2026-05-22T11:46:13.470025+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zoetis Q1 2025 revenue $2.2B (+9% organic), adj EPS $1.48; affirms 6-8% organic growth for FY","bullets":["Revenue $2.2B (+1% reported, +9% organic operational); net income $631M, diluted EPS $1.41.","Adjusted net income $662M, adj diluted EPS $1.48; +6% organic operational growth YoY.","U.S. segment revenue $1.2B (+6% organic); International $1.0B (+11% organic on operational basis).","FY25 guidance: revenue $9.425-9.575B (6-8% organic); adj diluted EPS $6.20-6.30, reflecting FX and tariffs.","Simparica Trio gains U.S. flea tapeworm label; avian influenza vaccine conditional license in U.S./Canada."],"urls":{"canonical":"https://secwatch.observer/filing/0001555280-25-000201","json":"https://secwatch.observer/filing/0001555280-25-000201.json","markdown":"https://secwatch.observer/filing/0001555280-25-000201.md","text":"https://secwatch.observer/filing/0001555280-25-000201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555280/000155528025000201/0001555280-25-000201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555280/000155528025000201/zts-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:46:13.470025+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}